Who is sponsoring NCT04153175?

NCT04153175 is sponsored by Cerebral Therapeutics LLC.

What drugs are being tested in NCT04153175?

Interventions in NCT04153175: ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC), Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC).

What condition does NCT04153175 study?

NCT04153175 studies Refractory Epilepsy.

Is NCT04153175 still recruiting?

NCT04153175 is currently terminated. Last updated 13 March 2024.

Last reviewed 2024-03-13 · How we verify

NCT04153175

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study to Assess Intracerebroventricular (ICV) Delivery of CT-010 in Subjects With Focal Seizures, With Temporal Lobe Onset With or Without Secondary Generalization

Terminated Phase 2 Last updated 13 March 2024

What this trial tests

Phase 2 trial testing ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in Refractory Epilepsy in 30 participants. Terminated before completion.

Timeline

21 August 2020

Primary endpoint
1 March 2024

1 March 2024

Quick facts

Lead sponsor	Cerebral Therapeutics LLC
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	30
Start date	21 August 2020
Primary completion	1 March 2024
Estimated completion	1 March 2024
Sites	11 locations across Israel, Australia

Drugs / interventions tested

ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC)
Placebo delivery via an implantable pump and a cranial port and dual lumen catheter (CIC)

Conditions studied

Refractory Epilepsy — all drugs for Refractory Epilepsy →

Sponsor

Cerebral Therapeutics LLC — full company profile →

Who can join

Adults 18 to 70, any sex, with Refractory Epilepsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 2 double-blind, randomized, placebo-controlled study to assess the safety and efficacy of ICV delivery of CT-010 via an implantable pump and a cranial port and dual lumen catheter (CIC) in subjects with focal seizures, with temporal lobe onset with or without secondary generalization. Up to 70 subjects will be enrolled. Eligible subjects will be randomized in a 1:1 ratio to either CT-010 or placebo treatment. Up to 20 clinical centers will be enrolled.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Crossing the blood-brain barrier: emerging therapeutic strategies for neurological disease.
Pedder JH, Sonabend AM, Cearns MD, Michael BD, et al · · 2025 · cited 35× · PMID 39862873 · DOI 10.1016/s1474-4422(24)00476-9
Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery.
Meyer AH, Feldsien TM, Mezler M, Untucht C, et al · · 2023 · cited 15× · PMID 37111587 · DOI 10.3390/pharmaceutics15041100
Comparison of <i>MALAT1</i> antisense oligonucleotide distribution following intracerebroventricular and lumbar intrathecal routes of administration.
Boyd MM, Mazur C, Pribnow K, Zanon RL, et al · · 2025 · PMID 41216427 · DOI 10.1016/j.omtn.2025.102742

Verify or expand the search:

Other recruiting trials for Refractory Epilepsy

Currently open trials in the same condition.

NCT06425029 — Self-administered ONe-of-a Kind Approach to Epilepsy Therapy Through a Web-based Music Application · NA · recruiting
NCT06524479 — Investigating the Functional Characteristics During Wakefulness and Sleep Based on SEEG · NA · recruiting
NCT06241963 — High Definition Transcranial Direct Current Stimulation (HD-tDCS) for Refractory Epilepsy · NA · recruiting
NCT06396494 — An Automated Navigation System for Deep Brain Electrode Implantation · active not recruiting
NCT05493722 — Optimization of Deep Brain Stimulation Parameters in Patients With Medically Refractory Epilepsy · EARLY_PHASE1 · recruiting

Other Cerebral Therapeutics LLC trials

Trials by the same sponsor.

NCT04529954 — Anti-Epilepsy Medication Valproate Administered Via ICV Route and Catheters and Pumps for CSF Infusion · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04153175 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Cerebral Therapeutics LLC
Last refreshed: 13 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04153175.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing